Femasys (NASDAQ:FEMY) Releases Quarterly Earnings Results, Misses Expectations By $0.02 EPS

Femasys (NASDAQ:FEMY) posted its earnings results on Friday. The company reported ($1.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.31) by ($0.02), Zacks reports. Femasys had a negative return on equity of 258.08% and a negative net margin of 521.97%.The firm had revenue of $0.33 million for the quarter, compared to analyst estimates of $0.73 million.

Femasys Price Performance

Shares of FEMY remained flat at $2.29 during midday trading on Friday. 116,831 shares of the stock were exchanged, compared to its average volume of 170,721. The firm has a market capitalization of $6.92 million, a P/E ratio of -0.42 and a beta of -2.08. The business has a fifty day moving average price of $3.59 and a two-hundred day moving average price of $7.31. Femasys has a fifty-two week low of $2.19 and a fifty-two week high of $22.20. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.98 and a current ratio of 3.91.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on FEMY shares. Maxim Group cut their target price on shares of Femasys to $10.00 and set a “buy” rating on the stock in a research note on Friday. Wall Street Zen raised shares of Femasys to a “hold” rating in a research report on Saturday, June 13th. Finally, Weiss Ratings upgraded shares of Femasys from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, July 31st. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Femasys currently has a consensus rating of “Moderate Buy” and an average target price of $56.67.

Insiders Place Their Bets

In other Femasys news, CEO Kathy Lee-Sepsick purchased 15,625 shares of the business’s stock in a transaction on Friday, August 7th. The shares were bought at an average cost of $3.20 per share, for a total transaction of $50,000.00. Following the completion of the purchase, the chief executive officer directly owned 15,625 shares in the company, valued at approximately $50,000. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Dov Elefant purchased 15,625 shares of the firm’s stock in a transaction on Friday, August 7th. The shares were acquired at an average cost of $3.20 per share, with a total value of $50,000.00. Following the completion of the acquisition, the chief financial officer directly owned 15,625 shares in the company, valued at $50,000. The trade was a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last quarter, insiders have purchased 38,750 shares of company stock valued at $124,000. Insiders own 7.75% of the company’s stock.

Hedge Funds Weigh In On Femasys

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Kovack Advisors Inc. purchased a new position in Femasys in the fourth quarter valued at approximately $27,000. HRT Financial LP acquired a new stake in shares of Femasys during the fourth quarter worth about $30,000. Cetera Investment Advisers acquired a new stake in shares of Femasys during the fourth quarter worth about $36,000. Osaic Holdings Inc. purchased a new position in shares of Femasys during the second quarter worth about $45,000. Finally, State Street Corp grew its holdings in shares of Femasys by 43.5% during the fourth quarter. State Street Corp now owns 80,869 shares of the company’s stock worth $47,000 after buying an additional 24,500 shares during the last quarter. 65.27% of the stock is owned by institutional investors and hedge funds.

Femasys Company Profile

Femasys International, Inc is a medical device company focused on the research, development and commercialization of innovative technologies for interventional women’s health applications. The company’s core activities center on creating minimally invasive diagnostic and therapeutic products designed to address uterine cavity evaluation and treatment and to improve outcomes in gynecological care.

The company’s flagship product, the FemVue® hydrosonography system, is a single-use catheter-based device that enhances visualization of the uterine cavity through saline infusion sonography.